The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.
| Carolyn Cuff, Ph.D., Janssen (Co-Chair)
David Fox, M.D., University of Michigan (Co-Chair) Alexandre Akoulitchev, M.A., Ph.D., Oxford Biodynamics Tara Altepeter, M.D., FDA/CDER Niyanna Barron, M.B.A., OLINK Anne-Christine Bay-Jensen, Ph.D., Nordic Biosciences A/S Robert Benschop, Ph.D., Eli Lilly Maria Bettinotti, Ph.D., Association of Molecular Pathology (AMP) Jonathan Blackburn, Ph.D., Sengenics Alex Blasky, Ph.D., SomaLogic Mathias Blom, M.D., Ph.D., Rhino Health Preethi Chander, Ph.D., NIDCR/NIH Carol Feghali-Bostwick, Ph.D., National Scleroderma Foundation Chao Jiang, Ph.D., NIAID/NIH Kelly Chun, Ph.D., LabCorp Sahar Dawisha, M.D., FDA/CDRH Betty Diamond, Ph.D., Feinstein Institute Renee Donahue, Ph.D., NIH/NCI Thomas Fuerst, Ph.D., BioClinica Heath Guay, Ph.D., AbbVie Mireia Guerau, PharmD, PhD – NIH / NIAID Kathy Hammitt, M.A., Sjogren’s Foundation Caren Heller, M.D., MBA, Crohn’s & Colitis Foundation of America Andrea Hooper, Ph.D, Regeneron Julie Huang, Ph.D., Alector Robert Iannone, M.D., Jazz Pharmaceuticals Kathy Jung, Ph.D., NIH/NIAA Ernst Kriehuber, M.D., UCB David Martin, M.D., Pfizer |
Afsaneh Mozaffarian, Gilead
Bruce McManus, M.D., Ph.D., University of British Columbia Sumanta Mukherjee, Ph.D., GlaxoSmithKline Maik Muller, Ph.D., Biognosys Nikolay Nikolov, M.D., FDA/CDER Mariaelena Occhipinti, M.D., Ph.D., Radiomics Heiyoung Park, Ph.D., NIAMS/NIH Jane Parnes, M.D., Amgen Brian Porter, M.D., Ph.D., M.P.H., M.B.A., Novartis Barbara Radziszewska, Ph.D., M.P.H., NIH/NIA John Reveille, M.D., University of Texas Health Science Center (Houston) Lisa Rider, M.D., NIH/NIEHS Jonathan Robbins, M.D., Ph.D., Merck Jane Salmon, M.D., Hospital for Special Surgery Maggie Scully, Ph.D., Frederick National Laboratory for Cancer Research Susana A. Serrate-Sztein, M.D., NIH/NIAMS Glennda Smithson, Ph.D., Takeda Lisa Spain, Ph.D., NIH / NIDDK Emily Boyd Stormoen, Arthritis National Research Foundation Michael Townsend, Ph.D., Genentech Maria Vassileva, Ph.D., Arthritis Foundation Sudha Visvanathan, Ph.D., Boehringer Ingelheim Andrea Wagenfeld, Ph.D., Bayer Tony Wagner, Ph.D., Jazz Pharmaceuticals Ilan Wapinski, Ph.D., Sanofi Michael Weisman, M.D., Cedars-Sinai Medical Center Mary Wheatley, National Scleroderma Foundation Michael Whitfield, Ph.D., Dartmouth Geisel School of Medicine Philip Worboys, Ph.D., Sapient Bioanalytics |